{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:16:41Z","timestamp":1778969801609,"version":"3.51.4"},"reference-count":6,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:title>Summary<\/jats:title><jats:p>A 30-year-old man with a 10-year history of neurofibromatosis type 2 (NF-2) and minimal hearing in his left ear, presented with rapidly progressive disease and risk of total hearing loss. He was started on imatinib and achieved stable disease for 4\u2005months, after which the drug was ceased due to toxicity. He was then treated with bevacizumab for 8\u2005months with a best response of stable disease.<\/jats:p>","DOI":"10.1136\/bcr-2013-010274","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T06:13:24Z","timestamp":1373350404000},"page":"bcr2013010274","source":"Crossref","is-referenced-by-count":6,"title":["Imatinib in neurofibromatosis type 2"],"prefix":"10.1136","volume":"2013","author":[{"given":"Stephanie","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,7,8]]},"reference":[{"key":"2025042708313893000_2013.jul08_1.bcr2013010274.1","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1158\/0008-5472.CAN-08-4475","article-title":"Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate)","volume":"2013","author":"Mukherjee","year":"2009","journal-title":"Cancer Res"},{"key":"2025042708313893000_2013.jul08_1.bcr2013010274.2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","article-title":"Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2","volume":"2013","author":"Ammoun","year":"2011","journal-title":"Neuro Oncol"},{"key":"2025042708313893000_2013.jul08_1.bcr2013010274.3","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"2013","author":"Asthagiri","year":"2009","journal-title":"Lancet"},{"key":"2025042708313893000_2013.jul08_1.bcr2013010274.4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"2013","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"2025042708313893000_2013.jul08_1.bcr2013010274.5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"2013","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"key":"2025042708313893000_2013.jul08_1.bcr2013010274.6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ajmg.a.34359","article-title":"Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2","volume":"2013","author":"Blakeley","year":"2012","journal-title":"Am J Med Genet A"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-010274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T15:31:41Z","timestamp":1745767901000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-010274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,8]]},"references-count":6,"alternative-id":["10.1136\/bcr-2013-010274"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-010274","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,8]]}}}